Crown Bioscience, Inc. will open its new U.S. Research Center at the David H. Murdock Research Institute (DHMRI) in Kannapolis, NC, in 3Q14.
 
The new center will combine Crown’s existing cardiovascular and metabolic disease (CVMD) services with a new U.S. expansion of Crown oncology services. The CVMD business features several in vivo models including a collection of spontaneously diabetic monkeys, along with the addition of oncology services providing access to Crown’s collection of immune-oncology models. These include: Western patient-derived xenografts in humanized mice, murine tumor models, GEMM and autografts of spontaneous mouse tumors (MuPrime™).
 
The Kannapolis site will also offer new immunology technologies, including flow cytometry and immunoassays, and will also be able to access unique mouse strains available in the U.S.
 
Dr. Jean-Pierre Wery, president of Crown Bioscience, said, “The opening of a new center at DHMRI marks an important milestone for Crown. In addition to increasing our capacity for running Western patient derived PDX studies and trials, it presents the opportunity to expand and develop our new immunotherapeutic translational technology platforms. Relevant preclinical models to recapitulate clinical treatments are desperately needed and the Research Center will provide partners with a range of immunotherapy research platforms for preclinical drug development, including platforms of mouse and human immunity.”